ClinicalTrials.gg

Program

repaglinide

Also written as “Repaglinide”, “repaglinide and metformin combination tablet” and “Repaglinide/Metformin combination, Repaglinide, Metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Overweight · Gastrointestinal Stromal Tumors · Gout, led by 4 companies.

Furthest: phase 4, since Jun 25, 200718 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk130 open or runningphase 4since Jun 25, 2007Jun 25, 2007none ahead
Eli Lilly30 open or runningphase 1since Jul 20, 2022Jul 20, 2022none ahead
dalim-biotech-co-ltd10 open or runningphase 1since Jan 29, 2013Jan 29, 2013none ahead
Merck10 open or runningphase 4since Oct 16, 2012Oct 16, 2012none ahead

Also a collaborator on its studies: basilea-pharmaceutica-international-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 25, 2007First study: phase 4 study in Diabetes MellitusNew to Novo NordiskNovo Nordisk · NCT00491725 · 187 enrolled · China
  2. Dec 4, 20072 phase 4 studies in Diabetes MellitusNovo Nordisk · NCT00568984, NCT00568074
  3. Nov 26, 2008Phase 4 study in Diabetes MellitusNovo Nordisk · NCT00799448 · 40 enrolled · Greece
  4. Aug 13, 2009Phase 1 study in Diabetes MellitusNovo Nordisk · NCT00959101 · 42 enrolled · China
  5. Nov 26, 2009Phase 4 study in Diabetes MellitusNovo Nordisk · NCT01022762 · 440 enrolled · China
  6. Dec 8, 20112 phase 1 studies in Diabetes MellitusNovo Nordisk · NCT01490658, NCT01489644
  7. Mar 22, 2012Phase 3 study in Diabetes MellitusNovo Nordisk · NCT01562561 · 213 enrolled · Hong Kong, Malaysia, Philippines and more
  8. May 16, 2012Phase 4 study in Diabetes MellitusNovo Nordisk · NCT01605773 · 51 enrolled · United States
  9. Oct 1, 20123 phase 4 studies in Diabetes MellitusNovo Nordisk · NCT01698931, NCT01720303, NCT01720290
  10. Oct 16, 2012Merck's first study: phase 4 study in Diabetes Mellitus, Type 2New to MerckMerck · NCT01709305 · 5,570 enrolled
  11. Jan 29, 2013dalim-biotech-co-ltd's first study: phase 1 study in Diabetes Mellitus, Type 2New to dalim-biotech-co-ltddalim-biotech-co-ltd · NCT01780051 · 48 enrolled · Korea, Republic of
  12. Jul 20, 2022Eli Lilly's first study: phase 1 study in HealthyNew to Eli LillyEli Lilly · NCT05469113 · 16 enrolled · United States
  13. Nov 30, 2023Phase 1 study in HealthyEli Lilly · NCT06165146 · 16 enrolled · United States
  14. Jul 10, 2024Phase 1 study in HealthyEli Lilly · NCT06503679 · 49 enrolled · United States

TargetBeta

“Sulfonylurea receptor 1, Kir6.2 blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
mitiglinideruleKissei Pharmaceuticalphase 49

Studies

All 18 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06503679Healthy · United States1CompletedEli LillyDec 31, 202449
NCT06165146Healthy · United States1CompletedEli LillyDec 30, 202016
NCT05469113Healthy · United States1CompletedEli LillyMar 5, 201916
NCT01780051Diabetes Mellitus, Type 2 · Korea, Republic of1Completeddalim-biotech-co-ltdApr 201348
NCT01720303Diabetes Mellitus · China4CompletedNovo NordiskApr 10, 2003159
NCT01720290Diabetes Mellitus · China4CompletedNovo NordiskFeb 25, 2003150
NCT01709305Diabetes Mellitus, Type 24CompletedMerckApr 17, 20155,570
NCT01698931Diabetes Mellitus · Italy4CompletedNovo NordiskMar 6, 20039
NCT01605773Diabetes Mellitus · United States4CompletedNovo NordiskMar 13, 200351
NCT01562561Diabetes Mellitus · Hong Kong, Malaysia, Philippines and more3CompletedNovo NordiskDec 20, 2002213
NCT01490658Diabetes Mellitus · United States1CompletedNovo NordiskAug 200693
NCT01489644Diabetes Mellitus · United States1CompletedNovo NordiskJul 200662
NCT01022762Diabetes Mellitus · China4CompletedNovo NordiskNov 2010440
NCT00959101Diabetes Mellitus · China1CompletedNovo NordiskOct 200942
NCT00799448Diabetes Mellitus · Greece4TerminatedNovo NordiskSep 20, 200440
NCT00568984Diabetes Mellitus · China, Malaysia, Philippines and more4CompletedNovo NordiskNov 10, 2003324
NCT00568074Diabetes Mellitus · China4CompletedNovo NordiskSep 2, 2004131
NCT00491725Diabetes Mellitus · China4CompletedNovo NordiskJun 2006187

How it is read

Names in the registry

  • “Repaglinide”, 15 entries
  • “repaglinide”, 13 entries
  • “repaglinide and metformin combination tablet”, 2 entries
  • “Repaglinide/Metformin combination, Repaglinide, Metformin”, 2 entries
  • “repaglinide 0.5 mg tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.